Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Data-driven disease progression models are an emerging set of computational tools that
reconstruct disease timelines for long-term chronic diseases, providing unique insights into …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by
the loss of upper and lower motor neurons. Presently, three FDA-approved drugs are …

Advances in artificial intelligence have cultivated a strong interest in developing and
validating the clinical utilities of computer-aided diagnostic models. Machine learning for …

According to the Geroscience concept that organismal aging and age-associated diseases
share the same basic molecular mechanisms, the identification of biomarkers of age that can …

Neurofilament proteins have been validated as specific body fluid biomarkers of neuro-
axonal injury. The advent of highly sensitive analytical platforms that enable reliable …

Tauopathies are a group of neurodegenerative disorders characterized by the aggregation
of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed …

Neurodegenerative disorders exhibit considerable clinical heterogeneity and are frequently
misdiagnosed. This heterogeneity is often neglected and difficult to study. Therefore …

Objective To explore whether the utility of neurofilament light chain (NfL), as a biomarker to
aid amyotrophic lateral sclerosis (ALS) therapy development, would be enhanced by …